GU Cancers 2019 | Zuclomiphene citrate: overcoming the estrogenic side effects of ADT in mCRPC patients
Although androgen deprivation therapy (ADT) is accepted as the standard treatment for advanced prostate cancer, its associated adverse events (AEs) remains an issue in patients. ADT not only affects testosterone levels, but also lowers estrogen levels, leading to AEs such as hot flashes. Robert Getzenberg, PhD, of the NSU MD, Fort Lauderdale, FL, discusses the Phase II study (NCT03646162) investigating the effect of zuclomiphene citrate, a weak estrogen, on reducing the incidence of hot flashes in advanced prostate cancer patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up